A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Clinical trial NCT05658601 · COMPLETED
Trial details
- NCT number
- NCT05658601
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2023-07-14
- Primary completion
- 2025-07-03
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.